U.S. must address IP and market access barriers abroad to protect American innovation

PhRMA recently submitted comments to the Office of the U.S. Trade Representative (USTR)’s 2023 Special 301 Report. The comments highlight foreign government actions and policies that undermine...
Read More
Minnesota lawmakers are letting PBMs off the hook, and threatening patients’ access to medicines

Middlemen don’t want patients to know how they are stacking the deck against them.
Read More
New Report: More than 160 medicines in development for mental illness

Mental illness represents a broad spectrum of health conditions affecting mood, thinking and behavior. These conditions include depression, bipolar disorder, schizophrenia, substance use disorder,...
Read More
ICYMI: Cancer death rate continues to decline due to treatment advances

Earlier this month, the American Cancer Society (ACS) released its annual report, Cancer Statistics 2023, finding the overall cancer mortality rate has declined 33% since peaking in 1991, leading to...
Read More
Novel medicines approved in 2022 offer increased treatment options for patients

2022 marked another year of significant progress by biopharmaceutical research companies conducting lifesaving research and development for innovative medicines with a total of 45 new medicine...
Read More
ICYMI: PhRMA kicks off the year at the 2023 J.P. Morgan Health Care Conference

This January, PhRMA joined health care leaders, investors, R&D experts and members of the media at the 2023 J.P. Morgan Health Care Conference in San Francisco, CA. During this week, we discussed...
Read More
Biden administration should prioritize innovation in U.S.-Taiwan Initiative on 21st-Century Trade

Last summer, the United States and Taiwan launched the U.S.-Taiwan Initiative on 21st-Century Trade to deepen economic and trade relations. In detailed comments to the U.S. Trade Representative...
Read More
WTAS: Inflation Reduction Act already impacting R&D decisions

The Inflation Reduction Act’s (IRA’s) drug price setting provisions, as predicted, are already impacting biopharmaceutical research & development (R&D) decisions. Whether you are looking at estimates...
Read More
Study finds hepatitis C cure saved Medicaid $15 billion

New research published in the American Journal of Managed Care (AJMC) underscores the critical role that medicines play in improving health and reducing disease complications and other, often costly,...
Read More